Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Inovio (Beijing) Biomedical Technology Co., Ltd. is a biomedical technology company. According to its official website, its core focus is the R&D and clinical translation of stem cell and cellular immunotherapy products, as well as stem cell resource storage. Centered on “transplantation immunology” and “tumor immunology,” the company focuses on enhanced hematopoietic stem cell products, modified stem cell products, cytotoxic T cell products, universal CAR-T, and micro-transplantation-related application solutions.
Based on the information disclosed on its website, Inovio is more of an R&D and translational platform than a conventional online medical service platform. Its capabilities include cell therapy product development, research related to disease diagnosis and efficacy monitoring, technical reserves for hematologic transplantation diagnosis and treatment, transplantation immune testing, stem cell storage, and participation in national as well as provincial- and ministerial-level research projects. The company has around 1200㎡ of laboratory space, including a 1000㎡ GMP-standard laboratory and a stem cell storage facility, which form important infrastructure for its technology translation.
The official website does not disclose any standardized pricing, service packages, or patient-facing fee information. Given the nature of its business, actual collaboration is likely carried out through research projects, clinical studies, hospital partnerships, or corporate partnerships, with costs confirmed through offline negotiation.
Its strengths are a clearly defined technical direction, with a focus on cell therapies related to hematologic diseases, solid tumors, and autoimmune diseases. It also has a GMP R&D and production center, industry-academia-research partnerships, and high-tech enterprise qualifications. The website also presents academic content such as micro-transplantation topics, expert consensus documents, and group standards.
The main drawback is that the publicly available information is mostly corporate introduction. It lacks details such as the clinical stages of its product pipeline, registration and approval status, clinical trial numbers, verifiable efficacy data, and cooperation procedures. For patients, the website should not be used directly as a basis for treatment decisions; assessment should still be conducted through qualified hospitals and physicians.
It is better suited for medical institutions, research institutes, clinical research centers, and biopharmaceutical partners looking to understand its R&D capabilities or explore collaboration. General patients may use it as a source of background information, but should not independently judge treatment indications or efficacy based on the website.
The website has an ICP filing, the company is based in Beijing, and the Chinese interface is complete, so access from within mainland China should be direct. Overall, Inovio’s official website presents a relatively solid positioning in cell therapy R&D, though there is still room to improve information transparency.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on innovvy.com official site.
innovvy.com is an China other provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach innovvy.com directly.